A Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy
MM1OA-S03 is temporarily closed to accrual at 10:00 am Pacific Time on October 8, 2025.
(See required screening study MYELOMATCH)
